Base de dados : MEDLINE
Pesquisa : D12.776.124.486.485.114.664 [Categoria DeCS]
Referências encontradas : 12079 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1208 ir para página                         

  1 / 12079 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29350259
[Au] Autor:Zhu X; Zhang J; Wang Q; Fu H; Chang Y; Kong Y; Lv M; Xu L; Liu K; Huang X; Zhang X
[Ad] Endereço:Peking University People's Hospital, Peking University Institute of Hematology, Beijing, 100044, China.
[Ti] Título:Diminished expression of ß2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia.
[So] Source:Ann Hematol;97(4):641-654, 2018 Apr.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Anti-GPIIb/IIIa-mediated complement activation has been reported to be important in the pathogenesis of immune thrombocytopenia (ITP). However, the role of the complement system and the involved regulatory mechanism remain equivocal. Beta2-glycoprotein I (ß2-GPI), known as the main target for antiphospholipid autoantibodies, has been demonstrated as a complement regulator. Here, we investigated the complement-regulatory role of ß2-GPI in anti-GPIIb/IIIa-mediated ITP. Plasma complement activation and enhanced complement activation capacity (CAC) were found in ITP patients with anti-GPIIb/IIIa antibodies in vivo and in vitro. Diminished plasma levels of ß2-GPI were shown in patients of this group, which was inversely correlated with C5b-9 deposition. C5b-9 generation was inhibited by approximate physiological concentrations of ß2-GPI, in a dose-dependent manner. Inhibition of C3a generation by ß2-GPI and the existence of ß2-GPI/C3 complexes in plasma indicated a regulation on the level of the C3 convertase. Furthermore, ß2-GPI down-regulated the phosphorylation levels of c-Jun N-terminal kinase (JNK) and cleavage of BH3 interacting domain death agonist (Bid) and ultimately harbored platelet lysis. Our findings may provide a novel link between diminished plasma levels of ß2-GPI and enhanced complement activation, indicating ß2-GPI as a potential diagnostic biomarker and therapeutic target in the treatment of anti-GPIIb/IIIa-mediated ITP.
[Mh] Termos MeSH primário: Ativação do Complemento
Regulação para Baixo
Isoanticorpos/metabolismo
Complexo Glicoproteico GPIIb-IIIa de Plaquetas/antagonistas & inibidores
Púrpura Trombocitopênica Idiopática/metabolismo
beta 2-Glicoproteína I/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Biomarcadores/sangue
Plaquetas/imunologia
Plaquetas/metabolismo
Plaquetas/patologia
China/epidemiologia
Convertases de Complemento C3-C5/metabolismo
Complemento C3a/metabolismo
Feminino
Seres Humanos
Masculino
Meia-Idade
Complexo Glicoproteico GPIIb-IIIa de Plaquetas/metabolismo
Complexo Glicoproteico GPIb-IX de Plaquetas/antagonistas & inibidores
Complexo Glicoproteico GPIb-IX de Plaquetas/metabolismo
Púrpura Trombocitopênica Idiopática/imunologia
Púrpura Trombocitopênica Idiopática/patologia
Púrpura Trombocitopênica Idiopática/fisiopatologia
Risco
Trombocitopenia/sangue
Trombocitopenia/imunologia
Trombocitopenia/metabolismo
Trombose/epidemiologia
Trombose/etiologia
Adulto Jovem
beta 2-Glicoproteína I/sangue
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Isoantibodies); 0 (Platelet Glycoprotein GPIIb-IIIa Complex); 0 (Platelet Glycoprotein GPIb-IX Complex); 0 (beta 2-Glycoprotein I); 0 (glycoprotein receptor GPIb-IX); 80295-42-7 (Complement C3a); EC 3.4.21.- (Complement C3-C5 Convertases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3215-3


  2 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457920
[Au] Autor:Kauke T; Link M; Rentsch M; Stangl M; Guba M; Andrassy J; Werner J; Meiser B; Fischereder M; Habicht A
[Ad] Endereço:Laboratory of Immunogenetics, University Hospital Munich, Germany; Clinic for General, Visceral-, Transplantation-, Vascular- and Thoracic Surgery, University Hospital Munich, Germany.
[Ti] Título:Antibody response to HBV vaccination on dialysis does not correlate with the development of deNovo anti-HLA antibodies after renal transplantation.
[So] Source:Transpl Immunol;42:5-8, 2017 06.
[Is] ISSN:1878-5492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Response to Hepatitis B virus (HBV) vaccination can be diminished in some (50-80%) but not all dialysis patients. We hypothesized, that the response to vaccination on dialysis may correlate with the development of anti-HLA antibodies after renal transplantation and might therefore be a valuable parameter to predict alloresponses. METHODS: The response to HBV vaccination on dialysis and the development of deNovo anti-HLA antibodies post-transplant was analyzed in 188 non-immunized renal transplant recipients. The response to HBV vaccination was evaluated by measuring the anti-HBs titer at time of transplantation. Anti-HLA antibodies post-transplant were monitored by serial measurements by means of Luminex. Acute rejection episodes, graft loss and renal dysfunction were assessed within a median follow-up of 5.5years. RESULTS: One hundred and forty-one patients (75%) exhibited an adequate immune response to HBV vaccination on dialysis. Vaccine responder (R) and none responder (NR) did not differ with respect to age, gender and BMI, while R spend significantly more time on dialysis before transplantation (4.58±3.35 vs 3.23±2.55 years, p=0.033). More NR developed deNovo anti-HLA antibodies (27.7 vs 22.7%, p=0.554) and donor-specific anti-HLA antibodies (23.4 vs 14.2%, p=0.173) in comparison to R. Accordingly, the number of acute rejections was higher in NR as compared to R (36.1 vs 24.1%, p=0.130) while graft survival was similar in both groups. CONCLUSION: Contrary to our hypothesis antibody response to HBV vaccination on dialysis does not predict the development of anti-HLA antibodies post transplant.
[Mh] Termos MeSH primário: Formação de Anticorpos
Rejeição de Enxerto/imunologia
Antígenos HLA/imunologia
Vacinas contra Hepatite B/administração & dosagem
Isoanticorpos/imunologia
Transplante de Rim
Diálise Renal
[Mh] Termos MeSH secundário: Adulto
Assistência ao Convalescente
Feminino
Vacinas contra Hepatite B/efeitos adversos
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HLA Antigens); 0 (Hepatitis B Vaccines); 0 (Isoantibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  3 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29377071
[Au] Autor:Rees DC; Robinson S; Howard J
[Ad] Endereço:Department of Haematological Medicine, King's College Hospital, King's College London, London, UK.
[Ti] Título:How I manage red cell transfusions in patients with sickle cell disease.
[So] Source:Br J Haematol;180(4):607-617, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Sickle cell disease is one of the commonest serious inherited diseases in the world, and red cell transfusion is still one of the few effective treatments for acute and chronic complications. Transfusion corrects anaemia and dilutes out the number of red cells able to cause vaso-occlusion and vascular damage. Urgent red cell transfusions are used to correct acute anaemia, treat acute chest syndrome and patients with acute neurological symptoms. We use elective transfusions preoperatively for moderate risk surgery, and in some pregnant women. There is good evidence for the use of long-term regular transfusions in primary stroke prevention, with the aim of keeping the percentage of sickle haemoglobin below 30%. Long-term transfusions are also used in secondary stroke prevention, and the management of progressive organ damage, including renal impairment and pulmonary hypertension. Blood needs to be matched for ABO, RH and Kell, although alloantibodies may still develop and require more careful, extended cross-matching. Delayed haemolytic transfusion reactions are relatively common, difficult to diagnose and manage, and potentially fatal.
[Mh] Termos MeSH primário: Anemia Falciforme/terapia
Transfusão de Eritrócitos
[Mh] Termos MeSH secundário: Fatores Etários
Anemia Falciforme/complicações
Anemia Falciforme/diagnóstico
Anemia Falciforme/etiologia
Doadores de Sangue
Gerenciamento Clínico
Transfusão de Eritrócitos/efeitos adversos
Transfusão de Eritrócitos/métodos
Genótipo
Seres Humanos
Disseminação de Informação
Isoanticorpos/sangue
Isoanticorpos/imunologia
Fenótipo
Fatores de Tempo
Reação Transfusional
Conduta Expectante
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Isoantibodies)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15115


  4 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29270992
[Au] Autor:Ljung RCR
[Ad] Endereço:Department of Clinical Sciences - Paediatrics, Lund University, Lund, Sweden.
[Ti] Título:How I manage patients with inherited haemophilia A and B and factor inhibitors.
[So] Source:Br J Haematol;180(4):501-510, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Development of inhibitors to coagulation factor VIII or IX is still the most challenging complication in haemophilia care. 'Bypassing agents' may be used to treat a bleed but the eradication of the inhibitor by immune tolerance induction (ITI) is the main objective in the treatment of a patient with haemophilia who has developed neutralizing antibodies. Several options exist for ITI and the patient may be at 'good' or 'bad risk' for successful outcome with different regimens. This paper offers a review of current regimens to be considered in the treatment of a bleed in a patient with an inhibitor but the main focus is the aspects of different choices in the management of the child or the adult with severe or mild forms of haemophilia A or B, who has developed an inhibitor. There are also some final outlooks on new and emerging treatment possibilities.
[Mh] Termos MeSH primário: Inibidores dos Fatores de Coagulação Sanguínea
Hemofilia A/diagnóstico
Hemofilia A/terapia
Hemofilia B/diagnóstico
Hemofilia B/terapia
Isoanticorpos
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Inibidores dos Fatores de Coagulação Sanguínea/sangue
Inibidores dos Fatores de Coagulação Sanguínea/imunologia
Criança
Gerenciamento Clínico
Fator IX/genética
Fator IX/imunologia
Fator IX/uso terapêutico
Fator VIII/genética
Fator VIII/imunologia
Fator VIII/uso terapêutico
Hemofilia A/complicações
Hemofilia A/genética
Hemofilia B/complicações
Hemofilia B/genética
Hemorragia/etiologia
Hemorragia/prevenção & controle
Hemorragia/terapia
Seres Humanos
Isoanticorpos/sangue
Isoanticorpos/imunologia
Medição de Risco
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Blood Coagulation Factor Inhibitors); 0 (Isoantibodies); 9001-27-8 (Factor VIII); 9001-28-9 (Factor IX)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15053


  5 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266059
[Au] Autor:Tambur AR; Wiebe C
[Ad] Endereço:Transplant Immunology Laboratory, Comprehensive Transplant Center, Northwestern University, Chicago, IL.
[Ti] Título:HLA Diagnostics: Evaluating DSA Strength by Titration.
[So] Source:Transplantation;102(1S Suppl 1):S23-S30, 2018 01.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:HLA antibodies, and specifically donor-specific-HLA antibodies, play a key role in transplant-related diagnostics and decision-making. It is now clear that the simple differentiation between absence and presence of HLA donor-specific antibodies does not provide sufficient granularity in all clinical circumstances. It addition, knowledge of HLA antibody strength has potential utility at different stages of recipient evaluation along the transplant timeline from initial pretransplant evaluation, evaluation of a specific potential donor, and posttransplant monitoring for de novo donor-specific antibodies. Here we compare data evaluating HLA antibody strength using the conventional IgG-mean fluorescence intensity approach with serial dilution studies (titration) and of C1q binding (C1q-mean fluorescence intensity). The added value of titration studies along the 3 milestones of the transplant cycle is emphasized.
[Mh] Termos MeSH primário: Complemento C1q/imunologia
Imunofluorescência/métodos
Rejeição de Enxerto/imunologia
Antígenos HLA/imunologia
Teste de Histocompatibilidade/métodos
Imunoglobulina G/sangue
Isoanticorpos/sangue
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Rejeição de Enxerto/prevenção & controle
Seres Humanos
Isoanticorpos/imunologia
Transplante de Órgãos
Assistência Perioperatória
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (HLA Antigens); 0 (Immunoglobulin G); 0 (Isoantibodies); 80295-33-6 (Complement C1q)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001817


  6 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266058
[Au] Autor:Lan JH; Tinckam K
[Ad] Endereço:Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Clinical Utility of Complement Dependent Assays in Kidney Transplantation.
[So] Source:Transplantation;102(1S Suppl 1):S14-S22, 2018 01.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Formation of antibodies against polymorphic HLA molecules on donor endothelium is central to the pathogenesis of antibody-mediated rejection, the dominant cause of long-term kidney allograft loss. Although introduction of the single-antigen bead assay has greatly facilitated the immune risk assessment of transplant recipients, it is recognized that not all IgG HLA antibodies detected using this method are equally relevant. In recent years, novel assays (C4d, C1q, C3d) have been developed to interrogate the complement-activating potential of anti-HLA antibodies in vitro, with the hypothesis that complement-fixing antibodies are more immediately injurious to the graft compared with noncomplement-binding antibodies. Although initial studies demonstrated the potential of these assays to risk-stratify antibodies beyond the conventional limited metric of mean fluorescence intensity values, new data from recent analyses challenge some of these early findings. In this review, we examine the technical aspects of these assays and key studies that evaluated the discriminant capacity of these tests to predict numerous outcomes in kidney transplantation. We discuss conflicting data and emerging controversies in the context of recent experimental evidence which offer new insights into the major factors that influence complement activation. Finally, we provide our perspective on the current role and utility of complement diagnostic assays as 1 variable in the multifactorial risk assessment and management of kidney transplant recipients.
[Mh] Termos MeSH primário: Ativação do Complemento/imunologia
Proteínas do Sistema Complemento/imunologia
Rejeição de Enxerto/imunologia
Antígenos HLA/imunologia
Teste de Histocompatibilidade/métodos
Isoanticorpos/metabolismo
Transplante de Rim
[Mh] Termos MeSH secundário: Biomarcadores/metabolismo
Rejeição de Enxerto/prevenção & controle
Seres Humanos
Isoanticorpos/imunologia
Medição de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (HLA Antigens); 0 (Isoantibodies); 9007-36-7 (Complement System Proteins)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001819


  7 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266057
[Au] Autor:Valenzuela NM; Schaub S
[Ad] Endereço:UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA.
[Ti] Título:The Biology of IgG Subclasses and Their Clinical Relevance to Transplantation.
[So] Source:Transplantation;102(1S Suppl 1):S7-S13, 2018 01.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Immunoglobulin G (IgG) is the dominant immunoglobulin and can be divided into 4 distinct subclasses. The evolution of IgG subclass switches is regulated by interaction with T cells and follows a 1-way direction (IgG3 → IgG1 → IgG2 → IgG4). Based on their structure, the 4 IgG subclasses can initiate different effector function such as complement activation, recruitment of various cells by Fc receptors, and agonistic signaling. Using current assays for HLA antibody detection as a template and replacing the generic reporter antibody with IgG subclass-specific reporter antibodies, it is possible to investigate the IgG subclasses of HLA antibodies. There are 15 different IgG subclass compositions possible. Based on the capability to activate the complement system and the class switch direction, 3 arbitrary patterns can be defined (ie, only complement-binding subclasses [IgG3 and/or IgG1], expansion to noncomplement-binding subclasses [IgG3 and/or IgG1 plus IgG2 and/or IgG4], and switch to noncomplement-binding subclasses [IgG2 and/or IgG4]). The latter group accounts for less than 5%, whereas the former 2 groups have a similar prevalence close to 50%. In the past 5 years, several studies correlated the IgG subclass pattern with occurrence of antibody-mediated rejection and allograft outcomes. Because of differences of the used IgG subclass assay, the time point of analyses, and the definition of outcomes, a clear picture has not emerged yet. Future needs are standardization of the assay, a more detailed knowledge of the initiated effector functions, and more well-designed clinical studies also looking at changes of the IgG subclass pattern over time.
[Mh] Termos MeSH primário: Antígenos HLA/imunologia
Teste de Histocompatibilidade
Switching de Imunoglobulina/imunologia
Imunoglobulina G/imunologia
Isoanticorpos/imunologia
Transplante de Órgãos
[Mh] Termos MeSH secundário: Ativação do Complemento/imunologia
Seres Humanos
Imunoglobulina G/classificação
Imunoglobulina G/genética
Isoanticorpos/classificação
Isoanticorpos/genética
Receptores Fc/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (HLA Antigens); 0 (Immunoglobulin G); 0 (Isoantibodies); 0 (Receptors, Fc)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001816


  8 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266056
[Au] Autor:Liwski RS; Gebel HM
[Ad] Endereço:Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
[Ti] Título:Of Cells and Microparticles: Assets and Liabilities of HLA Antibody Detection.
[So] Source:Transplantation;102(1S Suppl 1):S1-S6, 2018 01.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The evolution of antibody detection from cell- to bead-based technology has positively impacted the ability to allocate organs in a safe and timely manner. The devil, of course, is in the details that delineate how these assays are performed and applied and to recognize that while there have been some truly amazing technological advances (assets), they are still imperfect and subject to error (liabilities). This review identifies the strengths of HLA antibody assays, highlights their weaknesses and offers approaches for standardization.
[Mh] Termos MeSH primário: Micropartículas Derivadas de Células/imunologia
Antígenos HLA/imunologia
Teste de Histocompatibilidade/métodos
Isoanticorpos/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores/metabolismo
Teste de Histocompatibilidade/normas
Seres Humanos
Transplante de Órgãos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (HLA Antigens); 0 (Isoantibodies)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001818


  9 / 12079 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452922
[Au] Autor:O'Leary JG; Smith C; Cai J; Hart B; Jennings LW; Everly M; Klintmalm GB; Demetris AJ
[Ad] Endereço:1 Annette C. & Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas TX. 2 Terasaki Foundation Laboratory, Los Angeles, CA. 3 Department of Pathology, University of Pittsburgh, Pittsburg, PA.
[Ti] Título:Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome.
[So] Source:Transplantation;101(9):2062-2070, 2017 09.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A proposed chronic antibody-mediated rejection (AMR) score has recently predicted 50%10-year death-censored allograft loss in patients with donor-specific alloantibodies (DSA) mean florescence intensity (MFI) greater than 10 000 and requires confirmation in patients with lower MFI (1000-10 000). METHODS: All patients who underwent liver transplantation from January 2000 to April 2009, had DSA (MFI ≥1000) in serum 10 to 14 months postliver transplantation, and had a protocolized liver biopsy were evaluated (n = 230). The previously proposed chronic AMR (cAMR) score was used to risk-stratify putative chronic AMR in DSA+ patients with MFI from 1000 to 10 000. RESULTS: The MFI distribution of DSA+ recipients were as follows: 66% had MFI 1000 to 4999, 14% had MFI 5000 to 10 000, and 20% had MFI greater than 10 000. The cAMR score distribution on 1-year protocol liver biopsy found that 41% had a score less than 13; 27% a score of 13 to 27.5, and 32% a score greater than 27.5. MFI correlated with 1-year cAMR category (<13, 46% vs 21% and >27.5, 29% vs 42% when MFI was 1000-10 000 vs MFI >10 000; P = 0.047). In patients with a cAMR score less than 13, 10-year death-censored allograft survival was 96% to 100% regardless of MFI (P = NS). The risk of allograft loss increased in patients with a cAMR score greater than 13 (P = 0.004) in DSA+ patients with MFI 1000 to 10 000. DSA MFI greater than 10 000 versus MFI 1000 to 10 000 at 1 year was also more likely to persist at 5 years (95% vs 68%; P < 0.0001). CONCLUSIONS: Validation of the previously proposed cAMR score in a separate cohort predicts death-censored long-term allograft failure in DSA+ patients regardless of MFI, and higher MFI at 1 year predicts DSA persistence at 5 years.
[Mh] Termos MeSH primário: Técnicas de Apoio para a Decisão
Rejeição de Enxerto/diagnóstico
Sobrevivência de Enxerto
Isoanticorpos/imunologia
Transplante de Fígado/efeitos adversos
[Mh] Termos MeSH secundário: Aloenxertos
Biópsia
Doença Crônica
Feminino
Rejeição de Enxerto/imunologia
Rejeição de Enxerto/mortalidade
Rejeição de Enxerto/terapia
Seres Humanos
Imuno-Histoquímica
Isoanticorpos/sangue
Estimativa de Kaplan-Meier
Testes de Função Hepática
Transplante de Fígado/mortalidade
Masculino
Meia-Idade
Valor Preditivo dos Testes
Reprodutibilidade dos Testes
Medição de Risco
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Isoantibodies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001802


  10 / 12079 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27776015
[Au] Autor:Chong AS
[Ad] Endereço:1 Section of Transplant, Department of Surgery, The University of Chicago, Chicago, IL.
[Ti] Título:From Pipe Dream to Donor-Specific PC Elimination: Novel Ways to Target Alloantibodies.
[So] Source:Transplantation;100(11):2238-2239, 2016 11.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Isoanticorpos/imunologia
Doadores de Tecidos
[Mh] Termos MeSH secundário: Rejeição de Enxerto/imunologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; COMMENT
[Nm] Nome de substância:
0 (Isoantibodies)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180110
[Lr] Data última revisão:
180110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE



página 1 de 1208 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde